<DOC>
	<DOCNO>NCT02985372</DOCNO>
	<brief_summary>This prospective multicenter clinical study design ass efficacy safety decitabine combination low-dose cytarabine induction treatment elderly patient newly diagnose acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Decitabine Combination With Low-dose Cytarabine Elderly Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>All patient treat decitabine 15 mg/ m2 intravenously 4h 5 consecutive day ( day 1-5 ) priming combine cytarabine 10 mg/m2 q12h 10 day ( day 4-13 ) . Hydroxyurea permit rescue medication white blood count ( WBC ) &gt; 20×109/L discontinue least 24h decitabine treatment . Supportive care include blood product transfusion , G-CSF , antiemetic medication , antiviral antifungal medication , empiric antibiotic may use clinical discretion investigator . Curative effect evaluate two cycle : 1 . &lt; 5 % blast marrow , enter maintenance therapy ( Group A ) 2 . ≥5 % blast marrow , continue induction therapy two cycle , ① &lt; 5 % blast marrow , enter maintenance therapy ( Group B ) ; ② ≥5 % blast marrow , drop study ( Group C ) 3. marrow blast decline &lt; 60 % , drop study ( Group C ) . Maintenance therapy regimen : 1 . Ara-C 1g/m2/d iv drip d1-4 1 cycle 2 . DEC 15mg/m2/d iv drip d1-5 1 cycle 3 . Ara-C 1g/m2/d iv drip d1-4 1 cycle 4 . DEC 15mg/m2/d iv drip d1-5 1 cycle</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Patients previously untreated nonM3 AML ( diagnose WHO2016 criterion ) . 2 . Age : ≥ 60 ≤ 75 year . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 4 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5x upper limit normal ( ULN ) , total bilirubin ≤ 1.5 ULN , serum creatinine &lt; 2ULN . 5 . Without central nervous system symptom . 6 . Willing accept followup . 7 . Normal heart function ( EF &gt; 50 % ) . The subject volunteer sign inform consent . 1 . With severe cardiac , renal hepatic insufficiency . 2 . With cancer require treatment . 3 . With hematological disease ( e.g . Hemophilia , myelofibrosis , etc. ) . 4 . With severe infection metabolic disease ( include tuberculosis pulmonary aspergillosis ) . 5 . Brain disorder severe mental disease could limit compliance study requirement . 6 . Major operation within 3 week . 7 . With HIV infection AIDSassociated diseases . 8 . Any drug abuse , medical , mental social situation would affect result . 9 . Hypersensitivity cytarabine ( include drug fever exanthema ) decitabine .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>